Galera Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
101 LINDENWOOD DRIVE, MALVERN, PA, 19355
Mailing Address
101 LINDENWOOD DRIVE, MALVERN, PA, 19355
Phone
610-725-1500
Fiscal Year End
1231
EIN
461454898
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 3, 2026 | View on SEC |
| 10-K Annual financial report | March 19, 2026 | View on SEC |
| 8-K Current report of material events | February 18, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | November 24, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| 8-K Current report of material events | October 27, 2025 | View on SEC |
| 8-K Current report of material events | October 21, 2025 | View on SEC |
| 8-K Current report of material events | September 3, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 13, 2025 | View on SEC |
Annual Reports
10-K
March 19, 2026
- Successfully executed a bold strategic pivot, selling old drug assets and acquiring a new focus on aggressive breast cancers.
- New pan-NOS inhibitor for breast cancer is in a NIH-funded Phase 1/2 trial, with Phase 2a expanded to more centers in 2025.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.